Moreover, our results support that the tumour-promoting effects associated with the enhanced migration of high SMAD3 fibroblasts could be prevented with Trametinib or other MEK inhibitors in ADC but not SCC, since high SMAD2 fibroblasts as in SCC-TAFs were largely non-responsive to MEK inhibition. The gene discussed is SMAD3; the disease is neoplasm.